Isis Pharmaceuticals

Most Recent

  • uploads///Graph Part
    Company & Industry Overviews

    IBB Mid-Cap Outperforms XBI Mid-Cap

    IBB mid-cap outperformed XBI mid-cap for the week ended September 4, 2015. The IBB top ten mid-cap stocks returned -3.34%, while the XBI top ten mid-cap stocks returned -4.33% for the same period.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam and ISIS Lead Mid-Cap Stocks

    Alnylam and ISIS led mid-cap stocks from August 25–31, 2015. Alnylam Pharmaceuticals (ALNY) has a weight of 1.60% in IBB and 1.15% in XBI. The stock gained 10.89% in that period.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Biogen: An Investor’s Overview to a Leading Biotech Company

    One of the world’s leading biotechnology companies, Biogen specializes in manufacturing and marketing therapies to treat serious ailments related to the nervous system, immune system, and blood.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.